The company specializes in researching and developing new medicines in the areas of cancer treatment, surgical medicines, endocrine therapy, cardiovascular drugs, and anti-infection medications. They have 12 innovative products and more than 60 candidates in the R&D stage, with over 260 trials under clinical development worldwide. Hengrui is ranked 24th among the top 1,000 global pharma companies and has been on the Pharma Exec’s annual listing of top global pharmaceutical companies for four consecutive years.